Data from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

MLA

Robert L. Yauch, et al. Data from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6520997.v1.

APA

Robert L. Yauch, Amy Peterson, Premal Patel, See-Chun Phan, Lukas Amler, Vanitha Ramakrishnan, Mirella Lazarov, Jenny Huang, Marina Lipkind, Ignacio Wistuba, David S. Shames, Ellen Filvaroff, Sharianne G. Louie, Tom Januario, Xiaoling Xia, Vaishali Parab, An Do, Ling Fu, Rupal Desai, … Hartmut Koeppen. (2023). Data from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. https://doi.org/10.1158/1078-0432.c.6520997.v1

Chicago

Robert L. Yauch, Amy Peterson, Premal Patel, See-Chun Phan, Lukas Amler, Vanitha Ramakrishnan, Mirella Lazarov, et al. 2023. “Data from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit,” March. doi:10.1158/1078-0432.c.6520997.v1.